{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:08:59Z","timestamp":1791605339517,"version":"4.3.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.4158\/ep-2019-0596","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T13:14:44Z","timestamp":1583932484000},"page":"777-786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture"],"prefix":"10.1016","volume":"26","author":[{"given":"Felicia","family":"Cosman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP-2019-0596_bb0010","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP-2019-0596_bb0015","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2019-0596_bb0020","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP-2019-0596_bb0025","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4158\/EP161435.ESGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis--2016--executive summary","volume":"22","author":"Camacho","year":"2016","journal-title":"Endocr Pract"},{"key":"10.4158\/EP-2019-0596_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP-2019-0596_bb0035","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/BOR.0000000000000616","article-title":"The evolving role of anabolic therapy in the treatment of osteoporosis","volume":"31","author":"Cosman","year":"2019","journal-title":"Curr Opinion Rheumatol"},{"key":"10.4158\/EP-2019-0596_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.3039","article-title":"Goal-directed treatment for osteoporosis: a progress report from the ASBMRNOF working group on goal-directed treatment for osteoporosis","volume":"32","author":"Cummings","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Min Res"},{"key":"10.4158\/EP-2019-0596_bb0050","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/jbmr.3722","article-title":"Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment","volume":"34","author":"Ferrari","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3996","article-title":"T-score as an indicator of fracture risk on therapy: evidence from romosozumab vs alendronate treatment in the ARCH trial","author":"Cosman","year":"2020","journal-title":"Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0060","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00198-017-3976-5","article-title":"Imminent fracture risk","volume":"28","author":"Roux","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP-2019-0596_bb0065","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11914-010-0023-2","article-title":"Timing of subsequent fractures after an initial fracture","volume":"8","author":"van Geel","year":"2010","journal-title":"Curr Osteoporos Rep"},{"key":"10.4158\/EP-2019-0596_bb0070","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","article-title":"Risk of subsequent fracture after prior fracture among older women","volume":"30","author":"Balasubramanian","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP-2019-0596_bb0075","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00198-018-4502-0","article-title":"Characteristics of recurrent fractures","volume":"29","author":"Kanis","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP-2019-0596_bb0080","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.297.4.387","article-title":"Risk of subsequent fracture after low-trauma fracture in men and women","volume":"297","author":"Center","year":"2007","journal-title":"JAMA"},{"key":"10.4158\/EP-2019-0596_bb0085","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1359\/jbmr.060711","article-title":"Association between prior non-spine non-hip fractures or prevalent radiographic vertebral defomities known to be at least 10 years old and incident hip fracture","volume":"21","author":"Schousboe","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0090","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00198-017-3948-9","article-title":"Spine fracture prevalence in a nationally representative sample of US women and men aged \u226540 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013\u20132014","volume":"28","author":"Cosman","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP-2019-0596_bb0095","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"JAMA."},{"key":"10.4158\/EP-2019-0596_bb0100","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","article-title":"Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial","volume":"33","author":"Delmas","year":"2003","journal-title":"Bone"},{"key":"10.4158\/EP-2019-0596_bb0105","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00198-005-2026-x","article-title":"Risk of new clinical fractures within 2 years following a fracture","volume":"17","author":"van Helden","year":"2006","journal-title":"Osteoporosis Int"},{"key":"10.4158\/EP-2019-0596_bb0110","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/jbmr.1476","article-title":"Previous fractures at multiple sites increase the risk for subsequent fractures: The Global longitudinal Study of Osteoporosis in Women","volume":"27","author":"Gehlbach","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0115","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jbmr.5650070608","article-title":"Appendicular bone mineral and a woman's lifetime risk of hip fracture","volume":"7","author":"Black","year":"1992","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0120","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00198-008-0779-8","article-title":"Remaining life-time and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women","volume":"20","author":"Lippuner","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP-2019-0596_bb0125","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2019-0596_bb0130","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2019-0596_bb0135","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2019-0596_bb0140","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1\u201334)] are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol Pathol"},{"key":"10.4158\/EP-2019-0596_bb0145","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"10.4158\/EP-2019-0596_bb0150","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00198-008-0766-0","article-title":"Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis","volume":"20","author":"Lindsay","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP-2019-0596_bb0155","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00198-016-3534-6","article-title":"Teriparatide for osteoporosis: importance of the full course","volume":"27","author":"Lindsay","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP-2019-0596_bb0160","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","article-title":"The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis","volume":"18","author":"Marcus","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0165","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.4158\/EP-2019-0596_bb0170","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00198-019-04890-2","article-title":"Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis","volume":"30","author":"Watts","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP-2019-0596_bb0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jbmr.2991","article-title":"Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0180","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/jbmr.3411","article-title":"Management of patients with high baseline hip fracture risk by FRAX reduces hip fractures-a post hoc analysis of the SCOOP Study","volume":"33","author":"McCloskey","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0185","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000001080","article-title":"Effects of abaloparatide on bone mineral density and risk of fracture in post-menopausal women aged 80 years or older with osteoporosis","volume":"25","author":"McClung","year":"2018","journal-title":"Menopause"},{"key":"10.4158\/EP-2019-0596_bb0190","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00223-017-0375-z","article-title":"Geography of fracture incidence in post-menopausal women with osteoporosis treated with abaloparatide","volume":"102","author":"McClung","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"10.4158\/EP-2019-0596_bb0195","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jdiacomp.2018.08.016","article-title":"Determinants of fracture in adults with type 1 diabetes in the USA: results from the T1D Exchange Clinic Registry","volume":"32","author":"Dhaliwal","year":"2018","journal-title":"J Diabetes Complications"},{"key":"10.4158\/EP-2019-0596_bb0200","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1080\/03007995.2019.1656955","article-title":"Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial","volume":"35","author":"Bilezikian","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.4158\/EP-2019-0596_bb0205","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"key":"10.4158\/EP-2019-0596_bb0210","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jbmr.2152","article-title":"Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody","volume":"29","author":"Ominsky","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0215","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-forming and antiresorptive effects of romosozumab in postmenopausal osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0220","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2019-0596_bb0225","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jbmr.3439","article-title":"Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0230","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s007740170001","article-title":"Diagnostic criteria for primary osteoporosis: year 2000 revision","volume":"19","author":"Orimo","year":"2001","journal-title":"J Bone Miner Metab"},{"key":"10.4158\/EP-2019-0596_bb0235","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0240","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2019-0596_bb0245","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP-2019-0596_bb0250","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"10.4158\/EP-2019-0596_bb0255","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2019-0596_bb0260","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz162","article-title":"Effect of abaloparatide vs alendronate on fracture risk reduction in postmenopausal women with osteoporosis","author":"Leder","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2019-0596_bb0265","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial","volume":"92","author":"Cosman","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.4158\/EP-2019-0596_bb0270","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2019-0596_bb0275","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME Extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0280","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.4158\/EP-2019-0596_bb0285","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","article-title":"Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?","volume":"99","author":"Cosman","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP-2019-0596_bb0290","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2019-0596_bb0295","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0300","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"10.4158\/EP-2019-0596_bb0305","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0310","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2019-0596_bb0315","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/jbmr.1853","article-title":"Hip and spine strength effects of adding versus switching to teriparatide in post-menopausal women with osteoporosis treated with prior alendronate or raloxifene","volume":"28","author":"Cosman","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0320","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second course of romosozumab therapy following placebo or denosumab","volume":"30","author":"Kendler","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP-2019-0596_bb0325","unstructured":"KendlerDL, BoneHG, MassariF, et al. Retreatment with romosozumab after 12 months of placebo demonstrates similar BMD efficacy compared with initial romosozumab treatment. ENDO Annual Meeting 2017 [abstract]."},{"key":"10.4158\/EP-2019-0596_bb0330","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0335","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1\u201334) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0340","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bone.2016.05.004","article-title":"Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment","volume":"89","author":"Fahrleitner-Pammer","year":"2016","journal-title":"Bone"},{"key":"10.4158\/EP-2019-0596_bb0345","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-017-4304-9","article-title":"Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial","volume":"29","author":"Bilezikian","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP-2019-0596_bb0350","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jbmr.3003","article-title":"One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption","volume":"32","author":"Varela","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0355","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bone.2016.11.027","article-title":"One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats","volume":"95","author":"Varela","year":"2017","journal-title":"Bone"},{"key":"10.4158\/EP-2019-0596_bb0360","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","article-title":"Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1\u201334)","volume":"86","author":"Jolette","year":"2017","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.4158\/EP-2019-0596_bb0365","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1359\/jbmr.080807","article-title":"Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1\u201334)]","volume":"23","author":"Vahle","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0370","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","article-title":"The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years","volume":"27","author":"Andrews","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP-2019-0596_bb0375","first-page":"67","article-title":"The European postmarketing adult Osteosarcoma Surveillance Study: characteristics of patients, a preliminary report","volume":"80","author":"Von Scheele","year":"2009","journal-title":"Acta Orthopaedica"},{"key":"10.4158\/EP-2019-0596_bb0380","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s00198-018-4604-8","article-title":"The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years","volume":"29","author":"Gilsenan","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP-2019-0596_bb0385","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-020-05379-z","article-title":"Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab","author":"Cummings","year":"2020","journal-title":"Osteoporos Int"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20360201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20360201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:08:52Z","timestamp":1761516532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20360201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":76,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1530891X20360201"],"URL":"https:\/\/doi.org\/10.4158\/ep-2019-0596","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP-2019-0596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}